Oncolys BioPharma Inc. [4588]: Stock Price and Stock Information (including after-hours PTS trading)

According to the earnings report released on 7 August 2026, revenue increased 1,662.4% year on year to ¥500 million, mainly due to milestone income associated with manufacturing and marketing approval for OBP-301. Operating loss was ¥700 million and interim net loss was also ¥700 million, with the company remaining in the red, although the loss narrowed. The full-year earnings forecast remains undisclosed.

The approaching national drug price listing, insurance coverage and start of sales for OBP-301 are attracting attention ahead of its launch in Japan. The company has received milestone income and advance payments from its partner, FUJIFILM Toyama Chemical Co., Ltd., which could become a source of revenue going forward. The development of the supply chain, a review of inventory management and progress in overseas expansion have also been identified as important factors.

The company has a revenue opportunity from sales rights in the Taiwanese market through Medigen, with which it has signed a license agreement. Paid supply and royalty income are expected to begin after the product is launched locally. Greater negotiating power through stronger patent protection and progress in the clinical development of OBP-601 are also expected to drive long-term revenue.

Key points to monitor in future results include progress toward the national drug price listing and start of sales for OBP-301, expansion of overseas partnerships, and stable manufacturing and logistics operations. At the same time, risk factors remain, including income volatility due to reliance on milestone payments, dilution from new share issuances and funding challenges.